| 19 Nov 2026, 14:39 | BCAL Position on GSS-MAP Merger | Company Administration | MS | 12008 |
| 18 Nov 2026, 11:57 | Notification regarding unquoted securities - BDX | Securities Administration | — | 06021 |
| 18 Nov 2026, 11:54 | Change of Director's Interest Notice | Director Interests | — | 02009 |
| 17 Nov 2026, 08:43 | BCAL Expands Breast Cancer Biomarker Program | Company Update | — | 11001 |
| 13 Nov 2026, 17:44 | Notification of cessation of securities - BDX | Securities Administration | — | 06027 |
| 13 Nov 2026, 17:44 | Notification of cessation of securities - BDX | Securities Administration | — | 06027 |
| 13 Nov 2026, 17:38 | Application for quotation of securities - BDX | Securities Administration | — | 06020 |
| 13 Nov 2026, 17:29 | TOV: GSS - Panel Receives Application | Other | MS | — |
| 11 Nov 2026, 15:45 | Change of Director's Interest Notice | Director Interests | — | 02009 |
| 30 Oct 2026, 11:40 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 |
| 28 Oct 2026, 16:07 | BCAL Welcomes Dr John Melki's Appointment to GSS Board | Company Administration | — | 12008 |
| 19 Oct 2026, 14:14 | Results of Meeting | Meetings & Governance | — | 08003 |
| 19 Oct 2026, 10:43 | AGM 2026 Presentation | Presentations | — | 03026, 15002 |
| 19 Oct 2026, 09:27 | BREASTESTplus Research Presented at Lipidomic Conference | Presentations | — | 03026 |
| 16 Oct 2026, 20:25 | GSS: Response to Media Speculation & BCAL letter to GSS | Other | MS | — |
| 15 Oct 2026, 14:13 | Letter to Genetic Signatures Ltd Shareholders | Letters & Addresses | — | 16002 |
| 6 Oct 2026, 10:15 | Investor Presentation - Transforming Cancer Detection | Presentations | — | 03026 |
| 1 Oct 2026, 18:23 | Change in substantial holding | Substantial Holders | — | 02002 |
| 30 Sept 2026, 08:48 | BREASTESTplus 2 clinically validated | Company Update | MS | 11001 |
| 23 Sept 2026, 10:43 | BCAL Introduces Avantect Multi-Cancer Early Detection Test | Company Update | MS | 11001 |
| 18 Sept 2026, 08:22 | Letter to Shareholders re Annual General Meeting | Meetings & Governance | — | 08006, 16002 |
| 18 Sept 2026, 08:22 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 |
| 10 Sept 2026, 13:19 | Clarification of BCAL's Position in Relation to GSS | Other | — | 11004 |
| 3 Sept 2026, 12:40 | BCAL Seeks Board Change at Genetic Signatures | Company Administration | — | 12008 |
| 3 Sept 2026, 11:47 | Investor Presentation September 2026 | Presentations | — | 03026 |
| 31 Aug 2026, 14:30 | Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM | Presentations | — | 14014 |
| 28 Aug 2026, 15:46 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 |
| 28 Aug 2026, 15:44 | Appendix 4E and Annual Report to shareholders | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 |
| 26 Aug 2026, 08:57 | BCAL Takes Interest in Genetic Signatures to 18.46% | Substantial Holders | MS | 02006 |
| 26 Aug 2026, 08:35 | Change in Substantial Shareholder Notice for GSS | Other | — | — |
| 25 Aug 2026, 18:53 | Notification regarding unquoted securities - BDX | Securities Administration | — | 06021 |
| 21 Aug 2026, 18:27 | Notification regarding unquoted securities - BDX | Securities Administration | — | 06021 |
| 21 Aug 2026, 18:18 | Proposed issue of securities - BDX | Securities Administration | — | 06013 |
| 21 Aug 2026, 18:14 | BCAL Secures Funding for FY2027 Update | Periodic Reports | MS | 03014, 06009 |
| 6 Aug 2026, 09:34 | Bioshares Conference Investor Presentation | Presentations | — | 03026 |
| 30 July 2026, 08:38 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 |
| 14 July 2026, 18:51 | Notification regarding unquoted securities - BDX | Securities Administration | — | 06021 |
| 14 July 2026, 18:44 | Notification regarding unquoted securities - BDX | Securities Administration | — | 06021 |
| 14 July 2026, 18:32 | Notification regarding unquoted securities - BDX | Securities Administration | — | 06021 |
| 14 July 2026, 18:20 | Notification regarding unquoted securities - BDX | Securities Administration | — | 06021 |
| 2 July 2026, 17:13 | Becoming a substantial holder for GSS | Other | — | — |
| 2 July 2026, 10:04 | BCAL to Acquire Shares in Genetic Signatures | Company Update | MS | 11001 |
| 29 June 2026, 09:57 | BCAL Secures Funding for FY2027 | Periodic Reports | MS | 03014, 06009 |
| 18 June 2026, 09:52 | BCAL Develops New Blood Test for Breast Cancer Recurrence | Company Update | MS | 11001 |
| 28 May 2026, 08:25 | Validation Agreement Signed with Sonic USA, for Breastest V2 | Company Update | — | 11001 |
| 19 May 2026, 10:09 | BCAL Launches Early Detection Cancer Platform | Company Update | MS | 11001 |
| 11 May 2026, 08:23 | BCAL Appoints Anne-Louise Arnett as Chief Executive Officer | Company Administration | MS | 12017, 12019 |
| 22 Apr 2026, 08:50 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 |
| 31 Mar 2026, 09:11 | BCAL Submits MSAC Application for Avantect Pancreatic Test | Company Update | — | 11001 |
| 26 Mar 2026, 09:19 | BCAL Accelerates Rollout of Avantect Early Detection Tests | Company Update | MS | 11001 |